Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

Hilco Vision Acquires Bruder Healthcare

September 17, 2021

Medical Devices

Hilco Vision, a portfolio company of Windjammer Capital Investors, has acquired Bruder Healthcare effective September 17, 2021; terms were not disclosed. Bruder, a maker of therapeutic and ophthalmic dry-eye products based in Alpharetta, Georgia, will be integrated into Hilco’s product portfolio as the transaction represents a PE-backed add-on to expand Hilco’s offerings to eye care professionals and consumers.

Ares Management Acquires Majority Stake in Point Vision; Bpifrance Takes Minority Stake

October 12, 2021

Healthcare Services

Funds managed by the Private Equity Group of Ares Management acquired a majority stake in Point Vision, the French network of ophthalmology centers, while Bpifrance took a minority stake. The founders and key professionals are reinvesting as Point Vision plans to continue rolling out new centers across France and expand its services including teleconsultation and additional surgical specialties.

Bristol Myers Squibb Acquires Turning Point Therapeutics

June 3, 2022

Biotechnology

Bristol Myers Squibb agreed to acquire clinical-stage precision oncology company Turning Point Therapeutics in an all-cash transaction valuing the company at approximately $4.1 billion ($76.00 per share). The deal adds Turning Point's lead asset, repotrectinib, and its precision oncology pipeline to BMS's oncology franchise and is expected to close in 2022 (tender offer completed and merger subsequently closed).

Vistagen Acquires Pherin Pharmaceuticals

December 21, 2022

Biotechnology

Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.

BVI Acquires Benz Research & Development and SpecialEyes

October 15, 2020

Medical Devices

BVI, a PE-backed global ophthalmic medical device company, has acquired Benz Research & Development and its customized contact lens subsidiary SpecialEyes, both based in Sarasota, Florida. The deal expands BVI's intraocular lens (IOL) materials and contact lens capabilities — leveraging Benz's proprietary molding technology and materials (used in 50+ million implants) to increase IOL production scale and end-to-end capability.

Isoray Completes Merger with Viewpoint Molecular Targeting

February 6, 2023

Biotechnology

Isoray, Inc. completed an all-stock merger with Viewpoint Molecular Targeting, effective February 3, 2023, combining Isoray's brachytherapy expertise with Viewpoint's radiopharmaceutical and diagnostic pipeline. Under the deal each Viewpoint share converted into 3.1642 shares of Isoray (totaling 136,545,075 shares, ~49% of Isoray's outstanding shares); Viewpoint CEO Thijs Spoor was named CEO of the combined company and outgoing Isoray CEO Lori Woods became Chair.